What is MRVI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.93B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MRVI?

P/E (TTM) is n/a and 52-week range is $2.54 to $9.42 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MRVI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MRVI?

The company profile lists revenue (TTM) near $364M, net income (TTM) near $-13.50B, EPS (TTM) near $-0.53 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Maravai LifeSciences Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 258.2M shares outstanding, ISIN US56600D1072 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Maravai LifeSciences Holdings Inc

$MRVI

Health Care · Life Sciences Tools & Services

IR Run Scenarios

$7.44

+3.19%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Maravai Lifesciences Holdings, Inc. engages in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The company is headquartered in San Diego, California and currently employs 435 full-time employees. The company went IPO on 2020-11-20. Its segments include TriLink and Cygnus. Its TriLink segment provides nucleic acid products and related services, including messenger ribonucleic acid (mRNA), oligonucleotides, CleanCap mRNA capping technology, ModTail poly(A) tail modification technology, synthesis inputs, nucleoside triphosphates, enzymes, and mRNA manufacturing services. Its Cygnus segment provides biologics safety testing products and services, including host cell protein enzyme-linked immunosorbent assay (ELISA) kits, impurity detection assays, viral clearance prediction tools, ancillary reagents, and custom analytical services. Its TriLink and Cygnus segments produce materials used in research and biopharmaceutical production, clinical trial vaccines and vaccine support products.

Employees

435

Website

www.maravai.com/

IPO

2020-11-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)